Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05544019 · ClinicalTrials.gov registry record · Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
A Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Schrödinger.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT05544019: Recruiting Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Schrödinger.
NCT05544019 is a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Schrödinger. The registered enrollment target is 98 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05544019, a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Schrödinger.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Conditions Studied
Interventions
- DRUG SGR-1505
Study Locations (20)
Other
- AP-HP Hôpital Henri-Mondor - Créteil
- Institut Gustave Roussy - Villejuif
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile - Alessandria
- ASST Grande Ospedale Metropolitano Niguarda - Milan
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Weill Cornell - New York
- Montefiore Medical Center - The Bronx
Ohio
- Gabrail Cancer & Research Center - Canton
- The Ohio State University - The James Cancer Hospital - Columbus
Arizona
- Banner Health - MD Anderson Cancer Center - Gilbert
Delaware
- Christiana Care Hospital - Helen F Graham Cancer Center - Newark
Florida
- Napa Research - Pompano Beach
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Regional Cancer Care Associates - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
What NCT05544019 shows while recruiting
NCT05544019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (41% lower).
The record links to 10 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGR-1505 is the first listed.
NCT05544019 names 20 study sites across 14 states, led by Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05544019 about?
NCT05544019 is a clinical study titled "Study of SGR-1505 in Mature B-Cell Neoplasms". The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
What is the current status of trial NCT05544019?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-04-10. Estimated completion is 2027-11.
What conditions does trial NCT05544019 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, DLBCL.
What interventions are being tested in trial NCT05544019?
The interventions under investigation include: SGR-1505 (DRUG).
Who is sponsoring clinical trial NCT05544019?
This trial is sponsored by Schrödinger, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05544019 being conducted?
This trial has 20 study locations across Arizona, Delaware, Florida, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05544019's enrollment target sits among peer trials
98 40th of 106 higher than 67 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI